Novel drug research and development ability in China: An international comparison and analysis
10.3969/j.issn.1674-2982.2017.08.005
- VernacularTitle:我国创新药物研发能力的国际比较及成因分析
- Author:
Lin WU
1
;
fa Yong CHEN
Author Information
1. 中国药科大学国际医药商学院 江苏南京 211198
- Keywords:
Novel drug;
Research and development ability;
Policy reasons;
International comparison
- From:
Chinese Journal of Health Policy
2017;10(8):23-28
- CountryChina
- Language:Chinese
-
Abstract:
Under the background of innovation-driven development and advanced biopharmaceutical innovative construction,this paper selects the indicators from three aspects:capital investment,talent resources and innovation output,and a comparative evaluation of the innovation drug R&D ability of China and the developed countries namely United States,Japan and Europe,as the basis to reveal the policy causes of the innovation ability discrepancies in China.The empirical results show that the total amount of funds invested in R&D of innovative drugs is increasing and the number of R&D personnel has become the scale.However,the investment intensity is still far from that of the developed countries,and the capital investment structure is also deficient of rationality.This is inseparable from the absence of preferential taxation policies,lack of high-level personnel training,environmental defects in production and research,and narrow coverage of health insurance policies.
